{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Lung+Adenocarcinoma&page=3",
    "query": {
      "condition": "Refractory Lung Adenocarcinoma",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 74,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Lung+Adenocarcinoma&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Lung+Adenocarcinoma&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T10:23:50.798Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00003666",
      "title": "Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "6-hydroxymethylacylfulvene",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 36,
      "start_date": "1998-11",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2016-07-20",
      "last_synced_at": "2026-10-07T10:23:50.798Z",
      "location_count": 48,
      "location_summary": "Birmingham, Alabama • La Jolla, California • San Francisco, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003666"
    },
    {
      "nct_id": "NCT03728361",
      "title": "Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Grade I Neuroendocrine Carcinoma",
        "Grade II Neuroendocrine Carcinoma",
        "Grade III Neuroendocrine Carcinoma",
        "Metastatic Neuroendocrine Carcinoma",
        "Neuroendocrine Carcinoma",
        "Recurrent Small Cell Lung Carcinoma",
        "Refractory Small Cell Lung Carcinoma",
        "Lung Cancer Stage IV",
        "Large Cell Neuroendocrine Carcinoma",
        "Neuroendocrine Tumors",
        "Small Cell Lung Cancer Metastatic",
        "Small-cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Dwight Owen",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2018-12-31",
      "completion_date": "2025-12-02",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-10-07T10:23:50.798Z",
      "location_count": 2,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03728361"
    },
    {
      "nct_id": "NCT01638533",
      "title": "Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioma",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Lymphoma",
        "Metastatic Malignant Solid Neoplasm",
        "Neuroendocrine Neoplasm",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Recurrent Bladder Carcinoma",
        "Recurrent Breast Carcinoma",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Colorectal Carcinoma",
        "Recurrent Head and Neck Carcinoma",
        "Recurrent Lung Carcinoma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Melanoma",
        "Recurrent Pancreatic Carcinoma",
        "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Recurrent Prostate Carcinoma",
        "Recurrent Renal Cell Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
        "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Stage III Breast Cancer AJCC v7",
        "Stage III Colorectal Cancer AJCC v7",
        "Stage III Cutaneous Melanoma AJCC v7",
        "Stage III Lung Cancer AJCC v7",
        "Stage III Pancreatic Cancer AJCC v6 and v7",
        "Stage III Prostate Cancer AJCC v7",
        "Stage III Renal Cell Cancer AJCC v7",
        "Stage III Soft Tissue Sarcoma AJCC v7",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIA Colorectal Cancer AJCC v7",
        "Stage IIIA Cutaneous Melanoma AJCC v7",
        "Stage IIIB Breast Cancer AJCC v7",
        "Stage IIIB Colorectal Cancer AJCC v7",
        "Stage IIIB Cutaneous Melanoma AJCC v7",
        "Stage IIIC Breast Cancer AJCC v7",
        "Stage IIIC Colorectal Cancer AJCC v7",
        "Stage IIIC Cutaneous Melanoma AJCC v7",
        "Stage IV Breast Cancer AJCC v6 and v7",
        "Stage IV Colorectal Cancer AJCC v7",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7",
        "Stage IV Lung Cancer AJCC v7",
        "Stage IV Pancreatic Cancer AJCC v6 and v7",
        "Stage IV Prostate Cancer AJCC v7",
        "Stage IV Renal Cell Cancer AJCC v7",
        "Stage IV Soft Tissue Sarcoma AJCC v7",
        "Stage IVA Colorectal Cancer AJCC v7",
        "Stage IVB Colorectal Cancer AJCC v7",
        "Unresectable Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Romidepsin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2012-08-03",
      "completion_date": "2020-09-01",
      "has_results": false,
      "last_update_posted_date": "2025-02-07",
      "last_synced_at": "2026-10-07T10:23:50.798Z",
      "location_count": 11,
      "location_summary": "Duarte, California • Sacramento, California • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01638533"
    },
    {
      "nct_id": "NCT03678883",
      "title": "9-ING-41 in Patients With Advanced Cancers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Pancreatic Cancer",
        "Sarcoma",
        "Renal Cancer",
        "Refractory Cancer",
        "Refractory Neoplasm",
        "Refractory Non-Hodgkin Lymphoma",
        "Pancreatic Adenocarcinoma",
        "Resistant Cancer",
        "Neoplasm Metastasis",
        "Neoplasm of Bone",
        "Neoplasm, Breast",
        "Neoplasm of Lung",
        "Neoplasms,Colorectal",
        "Neoplasms Pancreatic",
        "Malignant Glioma",
        "Malignancies",
        "Malignancies Multiple",
        "Bone Metastases",
        "Bone Neoplasm",
        "Bone Cancer",
        "Pancreas Cancer",
        "Pancreatic Neoplasms",
        "Breast Neoplasms",
        "Acute T Cell Leukemia Lymphoma"
      ],
      "interventions": [
        {
          "name": "9-ING-41",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine - 21 day cycle",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin.",
          "type": "DRUG"
        },
        {
          "name": "Lomustine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin.",
          "type": "DRUG"
        },
        {
          "name": "Nab paclitaxel.",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel.",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine - 28 day cycle",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actuate Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 350,
      "start_date": "2019-01-04",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-10-07T10:23:50.798Z",
      "location_count": 40,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Orange, California + 34 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03678883"
    },
    {
      "nct_id": "NCT04439266",
      "title": "Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Lymphoma",
        "Advanced Malignant Solid Neoplasm",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Refractory Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Crizotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2015-08-12",
      "completion_date": "2027-03-30",
      "has_results": true,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-10-07T10:23:50.798Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04439266"
    },
    {
      "nct_id": "NCT07227168",
      "title": "A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma HNSCC",
        "Non-Small Cell Lung Cancer NSCLC",
        "Esophageal Cancer",
        "Gastric Cancer",
        "Colorectal Cancer",
        "Pancreatic Ductal Adenocarcinoma (PDAC)",
        "Cervical Cancer",
        "Endometrial Cancer",
        "Urothelial Cancer"
      ],
      "interventions": [
        {
          "name": "STRO-004",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sutro Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2025-11-07",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-10-07T10:23:50.798Z",
      "location_count": 9,
      "location_summary": "San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 6 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07227168"
    },
    {
      "nct_id": "NCT00002947",
      "title": "Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Childhood Langerhans Cell Histiocytosis",
        "Gastrointestinal Carcinoid Tumor",
        "Head and Neck Cancer",
        "Intraocular Melanoma",
        "Islet Cell Tumor",
        "Kidney Cancer",
        "Lung Cancer",
        "Melanoma (Skin)",
        "Neoplastic Syndrome",
        "Neuroendocrine Carcinoma of the Skin",
        "Pheochromocytoma"
      ],
      "interventions": [
        {
          "name": "indium In 111 pentetreotide",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "1996-10",
      "completion_date": "2004-08",
      "has_results": false,
      "last_update_posted_date": "2014-07-02",
      "last_synced_at": "2026-10-07T10:23:50.798Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002947"
    },
    {
      "nct_id": "NCT00625456",
      "title": "Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Lung Cancer",
        "Renal Cell Carcinoma",
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jennerex Biotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2008-06",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2015-12-03",
      "last_synced_at": "2026-10-07T10:23:50.798Z",
      "location_count": 3,
      "location_summary": "Billings, Montana • Philadelphia, Pennsylvania • Greenville, South Carolina",
      "locations": [
        {
          "city": "Billings",
          "state": "Montana"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00625456"
    },
    {
      "nct_id": "NCT00004065",
      "title": "Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bladder Cancer",
        "Breast Cancer",
        "Colorectal Cancer",
        "Gastric Cancer",
        "Head and Neck Cancer",
        "Kidney Cancer",
        "Leukemia",
        "Lung Cancer",
        "Melanoma (Skin)",
        "Ovarian Cancer",
        "Prostate Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "tanespimycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1999-07",
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2013-06-24",
      "last_synced_at": "2026-10-07T10:23:50.798Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • New York, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004065"
    },
    {
      "nct_id": "NCT00441337",
      "title": "A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "Colorectal Cancer",
        "Malignant Melanoma",
        "Renal Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "MDX-1106",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2006-08",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2015-02-20",
      "last_synced_at": "2026-10-07T10:23:50.798Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • Detroit, Michigan • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00441337"
    }
  ]
}